Full video transcriptClick to expand
Auto-generated transcript of @dr.pinkbrain's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00I think was epic is going to become a much bigger thing than it actually is, even though it's just used for weight loss primarily right now.
- 0:06And I know a lot of people, like, they'll see celebrities and will be like, oh, I think she's on his epic, I think he's on his epic.
- 0:10And there's just so much new research and so many new private research that has been, like, publicly published yet,
- 0:15that I've been seeing and that I've been discussing with, like, the GI doctor starting at my rotation right now, that I just thought that you guys should know about.
- 0:21So they did a study and, like, I think it was published in 2024, but they found out that some of the glutide or was epic or wagovie
- 0:29was found to have a 40 to 70% decrease in the development of Alzheimer's dementia and patients with type 2 diabetes, which is just absolutely insane.
- 0:36They found that they had lower prescriptions for Alzheimer's dementia medication.
- 0:39And not only that, if you have sleep apnea, oesumptic might be the next course of treatment for you coming down the line in the future.
- 0:45There's so much evidence out there about how sleep apnea causes so many different, like, medical problems, especially down the line and gears down the line.
- 0:51And if you have obesity, then you can have something called obesity hypoventilation syndrome just because of the size.
- 0:56And not only just decreasing the risk of dementia or, like, treating sleep apnea and the obesity hypoventilation syndrome,
- 1:01it's also been found to help treat food addiction, uncontrollable shopping addiction, nicotine addiction, and even like people who are addicted to recreational drug use.
- 1:10And the biggest thing that's been found to help reduce the risk of developing alcohol use disorder to help with alcohol addiction.
- 1:16So I know that a lot of people make fun of other people who are on oesumptic and govie, and there's such a big, like, stigma around using these medications,
- 1:22but I think we're going to start to see so many different uses of these medications other than just weight loss and just to treat diabetes.
GLP-1 drugs and addiction, dementia, sleep apnea: what the evidence actually says
Quick answer
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are GLP-1 receptor agonists with expanding evidence bases beyond glycemic control and weight management. The creator references real 2024 research on dementia risk reduction and sleep apnea treatment, but conflates semaglutide and tirzepatide and presents early-stage addiction research alongside more established findings without distinguishing the strength of evidence behind each. Clinicians should be aware that patients may come in citing this type of content and expecting these drugs to address conditions well outside current approved indications.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 drugs and addiction, dementia, sleep apnea: what the evidence actually says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 drugs and addiction, dementia, sleep apnea: what the evidence actually says" from dr. anusha reddy. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are GLP-1 receptor agonists with expanding evidence bases beyond glycemic control and weight management.
The reason this review is not generic is the source wording and the canonical claim label "glp1 the new and ongoing research about ozempic and wegovy and it." In this clip, the useful excerpt is: "I think was epic is going to become a much bigger thing than it actually is, even though it's just used for weight loss primarily right now." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are GLP-1 receptor agonists with expanding evidence bases beyond glycemic control and weight management.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are GLP-1 receptor agonists with expanding evidence bases beyond glycemic control and weight management. The creator references real 2024 research on dementia risk reduction and sleep apnea treatment, but conflates semaglutide and tirzepatide and presents early-stage addiction research alongside more established findings without distinguishing the strength of evidence behind each. Clinicians should be aware that patients may come in citing this type of content and expecting these drugs to address conditions well outside current approved indications.
- Tirzepatide (Zepbound), not semaglutide (Ozempic), received FDA approval for obstructive sleep apnea in June 2024, based on the SURMOUNT-OSA trial published in NEJM.
- Wang et al. (2024, Alzheimer's and Dementia) found semaglutide associated with 40-70% lower Alzheimer's diagnosis rates in type 2 diabetes patients, but the study is observational and does not prove the drug prevents dementia.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Tirzepatide (Zepbound), not semaglutide (Ozempic), received FDA approval for obstructive sleep apnea in June 2024, based on the SURMOUNT-OSA trial published in NEJM.
- Wang et al. (2024, Alzheimer's and Dementia) found semaglutide associated with 40-70% lower Alzheimer's diagnosis rates in type 2 diabetes patients, but the study is observational and does not prove the drug prevents dementia.
- Klausen et al. (2023, eClinicalMedicine) reported lower alcohol use disorder rates among GLP-1 drug users in a large retrospective cohort, but no randomized trial data exists to confirm this effect in humans.
- GLP-1 receptors are present in brain reward circuits, which gives the addiction research a plausible biological rationale, but plausibility is not the same as clinical evidence.
- No GLP-1 drug is currently approved by the FDA to treat Alzheimer's disease, nicotine addiction, alcohol use disorder, or compulsive shopping.
- Semaglutide and tirzepatide are different molecules with different receptor profiles. Claims about one do not automatically apply to the other.
- Unpublished data shared informally in clinical settings carries no evidentiary weight and should not factor into treatment decisions.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @dr.pinkbrain actually say?
The creator claims semaglutide (Ozempic/Wegovy) is headed far beyond weight loss and diabetes, citing a study showing a "40 to 70% decrease in the development of Alzheimer's dementia" in type 2 diabetes patients. They also say it may treat sleep apnea, obesity hypoventilation syndrome, food addiction, shopping addiction, nicotine addiction, recreational drug use, and alcohol use disorder. They mention seeing "private research that has not been publicly published yet" and frame these uses as an emerging wave that will change the stigma around GLP-1 drugs.
To be clear: some of these claims have real, peer-reviewed support. Others are early-stage or frankly speculative. The creator bundles them together without distinguishing between FDA-approved uses, promising trial data, and loose observational findings, and that matters a lot when people are making health decisions.
Does the science back this up?
The dementia claim is the strongest one here, but it is still observational data, not a clinical trial. The sleep apnea claim has actual trial support. The addiction claims are real signals in the literature, but most are early-phase or based on retrospective data.
On dementia: a large 2024 study by Wang et al. published in Alzheimer's and Dementia analyzed over one million patients with type 2 diabetes and found semaglutide users had significantly lower rates of Alzheimer's diagnosis compared to users of other diabetes medications. The effect sizes were notable. But this is a retrospective cohort study, meaning it cannot prove causation. Patients prescribed semaglutide may differ in income, access to care, and baseline health from those on older drugs.
On sleep apnea: the SURMOUNT-OSA trial (Malhotra et al., 2024, New England Journal of Medicine) tested tirzepatide, not semaglutide, in patients with moderate-to-severe obstructive sleep apnea and obesity. It showed meaningful reductions in apnea-hypopnea index scores. The FDA approved tirzepatide for obstructive sleep apnea in June 2024. The creator attributes this to Ozempic/Wegovy specifically, which is an error worth noting.
On addiction: there is legitimate early-stage research. A 2023 analysis by Klausen et al. in eClinicalMedicine found GLP-1 receptor agonist users had lower rates of alcohol use disorder diagnoses. Animal studies support a dopamine-reward mechanism. But there are no large randomized controlled trials in humans yet for nicotine, shopping, or recreational drug addiction specifically.
What did they get wrong (or right)?
The creator gets partial credit on dementia and sleep apnea but makes two notable errors. First, the sleep apnea approval is for tirzepatide (Zepbound), not semaglutide. These are different drugs. Conflating them is a meaningful mistake when patients are making treatment inquiries. Second, citing "private research that has not been publicly published yet" as supporting evidence is not how science works. Unpublished data from a hallway conversation during a rotation is not evidence anyone can evaluate.
What they got right: the general direction of the research is real. GLP-1 receptors exist throughout the brain, including in reward-related regions, and the idea that these drugs affect more than just appetite is scientifically credible. The dementia association study they reference does appear to be the Wang et al. 2024 paper, and the figures they cite (40 to 70%) roughly match published effect estimates. That is more specificity than most TikTok health content manages.
What they got wrong beyond the tirzepatide error: framing all of this as near-certain future treatments understates how far most of these indications are from clinical use. "Uncontrollable shopping addiction" as a GLP-1 indication is based on a handful of case reports and animal studies. Presenting it alongside FDA-adjacent sleep apnea data without distinction does viewers a disservice.
What should you actually know?
If you are considering a GLP-1 medication, the evidence base matters for the specific condition you have. Here is where things actually stand as of mid-2025.
- Semaglutide is FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Those indications have robust trial data behind them.
- Tirzepatide (Zepbound) received FDA approval in 2024 for obstructive sleep apnea in adults with obesity. This is real and significant, but it is a different drug from Ozempic.
- The dementia association data is intriguing and worth watching, but no regulatory body has approved any GLP-1 drug to prevent or treat Alzheimer's disease. Observational associations are not the same as proven effects.
- Addiction research is early-stage. There are signals in the data, but no approved indication and no clinical protocol for using these drugs to treat nicotine or alcohol use disorder outside of a research setting.
- If you want to explore GLP-1 therapy, talk to a licensed clinician about your specific situation, not a TikTok video citing unpublished hallway conversations.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
dr. anusha reddy · TikTok creator
47.2K views on this video
The new and ongoing research about Ozempic and Wegovy and it’s treatment for not only weight loss and type 2 diabetes but also could be the next line for sleep apnea, addiction from nicotine, uncontrollable shopping, food, and drinking. Not to mention how it has decreased risk of dementia is amazing, but obviously these medications will need more research to look for Olympic side effects. ——————————————————————————————————————— Olympic 1 month results Olympic before and now Olympic transformatio
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about tirzepatide (zepbound), not semaglutide (ozempic), received fda approval for obstructive?
Tirzepatide (Zepbound), not semaglutide (Ozempic), received FDA approval for obstructive sleep apnea in June 2024, based on the SURMOUNT-OSA trial published in NEJM.
What does the video say about wang et al. (2024, alzheimer's?
Wang et al. (2024, Alzheimer's and Dementia) found semaglutide associated with 40-70% lower Alzheimer's diagnosis rates in type 2 diabetes patients, but the study is observational and does not prove the drug prevents dementia.
What does the video say about klausen et al. (2023, eclinicalmedicine) reported lower alcohol use disorder?
Klausen et al. (2023, eClinicalMedicine) reported lower alcohol use disorder rates among GLP-1 drug users in a large retrospective cohort, but no randomized trial data exists to confirm this effect in humans.
What does the video say about glp-1 receptors?
GLP-1 receptors are present in brain reward circuits, which gives the addiction research a plausible biological rationale, but plausibility is not the same as clinical evidence.
What does the video say about no glp-1 drug?
No GLP-1 drug is currently approved by the FDA to treat Alzheimer's disease, nicotine addiction, alcohol use disorder, or compulsive shopping.
What does the video say about semaglutide?
Semaglutide and tirzepatide are different molecules with different receptor profiles. Claims about one do not automatically apply to the other.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by dr. anusha reddy, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.